Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Sanjiv S. Agarwala, John T. Vetto, Rogerio I. Neves, Robert H.I. Andtbacka, Matthew H. Taylor, Richard S. Ungerleider, Adil Daud, Merrick I. Ross, Maki Tanaka, Aislyn D. Boran, Hung T. Khong, Kenneth F. Grossmann
Publikováno v:
Journal of Clinical Oncology. 34:9543-9543
9543Background: HF10 is a replication-competent oncolytic virus derived from HSV-1. We report on preliminary safety data and antitumor activity of HF10 + ipilimumab (ipi) combination in an ongoing Phase 2 trial in melanoma. Methods: Key entry criteri
Autor:
Maki Tanaka, Richard S. Ungerleider, Robert L. Ferris, Kenneth F. Grossmann, Aislyn D. Boran, Robert H.I. Andtbacka, Hung T. Khong
Publikováno v:
Molecular Cancer Therapeutics. 14:C111-C111
Background: Here, we report on safety, recommended HF10 dose, viral shedding in body fluids and overall (all target lesions) and local (injected lesion) antitumor activity in patients (pts) with superficial tumors (13 squamous cell carcinoma, 9 malig